Immunomodulation by anticancer cell cycle inhibitors

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400

Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway

Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.

Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.

Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J., Lanier, L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,272

Cellular Senescence: Defining a Path Forward

Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.005 · Cited by 3,225

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874

Innate or adaptive immunity? The example of natural killer cells

Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824

Immunogenic cell stress and death

Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353

Targeting immunogenic cell stress and death for cancer therapy

Galluzzi, L., Guilbaud, E., Schmidt, D. R., Kroemer, G., & Marincola, F. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00920-9 · Cited by 606

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

Yamaguchi, H., Hsu, J.-M., Yang, W., & Hung, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 512

Emerging evidence for adapting radiotherapy to immunotherapy

Galluzzi, L., Aryankalayil, M. J., Coleman, C. N., & Formenti, S. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00782-x · Cited by 389

Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer

Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C., & Galluzzi, L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00579-w · Cited by 218

Immunomodulation by targeted anticancer agents

Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212

Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment

Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 162

Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: an update review

Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152934 · Cited by 131

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications

Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1796002 · Cited by 108

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

Slamon, D. J., Fasching, P. A., Hurvitz, S. A., Chia, S., Crown, J. P., Martín, M., Barrios, C. H., Bardia, A., Im, S., Yardley, D. A., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231178125 · Cited by 110

Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors

Uzhachenko, R. V., Bharti, V., Ouyang, Z., Blevins, A., Mont, S., Saleh, N., Lawrence, H. A., Shen, C., Chen, S., Ayers, G. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108944 · Cited by 109

Autophagy in the cancer-immunity dialogue

Yamazaki, T., Pedro, J. M. B., Galluzzi, L., Kroemer, G., & Pietrocola, F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.003 · Cited by 80

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization

Yang, Y., Luo, J., Chen, X., Yang, Z., Mei, X., Ma, J., Zhang, Z., Guo, X., & Yu, X. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01693-w · Cited by 77

Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer

Petroni, G., Buqué, A., Yamazaki, T., Bloy, N., Liberto, M. D., Chen‐Kiang, S., Formenti, S. C., & Galluzzi, L. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3871 · Cited by 71

Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma

Yin, X., Wang, Z., Wang, J., Xu, Y., Kong, W., & Zhang, J. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1933332 · Cited by 52

Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?

Riess, C., Irmscher, N., Salewski, I., Strüder, D., Classen, C.-F., Große-Thie, C., Junghanß, C., & Maletzki, C. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09940-4 · Cited by 47

Targeting cyclin‐dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studies

Yousuf, M., Shamsi, A., Queen, A., Shahbaaz, M., Κhan, P., Hussain, A., Alajmi, M. F., Haque, Q. M. R., & Hassan, M. I. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29921 · Cited by 46

Circular RNAs in cell cycle regulation: Mechanisms to clinical significance

Xiao, W., Li, J., Hu, J., Wang, L., Huang, J. R., Sethi, G., & Ma, Z. (2021) · Cell Proliferation · doi:10.1111/cpr.13143 · Cited by 47

Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy

Petroni, G., Pillozzi, S., & Antonuzzo, L. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3325 · Cited by 52

Salvia miltiorrhiza in Breast Cancer Treatment: A Review of Its Phytochemistry, Derivatives, Nanoparticles, and Potential Mechanisms

Zhao, H., Han, B., Li, X., Sun, C., Zhai, Y., Li, M., Jiang, M., Zhang, W., Liang, Y., & Kai, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.872085 · Cited by 40

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Su, X., Li, J., Xu, X., Ye, Y., Wang, C., Pang, G., Liu, W., Liu, A., Zhao, C., & Hao, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05552-6 · Cited by 45

Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha

Sahu, A. D., Wang, X., Munson, P. B., Klomp, J. P. G., Wang, X., Gu, S. S., Qian, G., Nicol, P., Zeng, Z., Wang, C., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0244 · Cited by 35

Immunomodulatory effects of CDK4/6 inhibitors

Zhang, S., Xu, Q., Sun, W., Zhou, J., & Zhou, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188912 · Cited by 34

Function of p21 and its therapeutic effects in esophageal cancer (Review)

Wang, L., Han, H., Dong, L., Wang, Z., & Qin, Y. (2020) · Oncology Letters · doi:10.3892/ol.2020.12397 · Cited by 36

Targeting CDK7 in oncology: The avenue forward

Li, Z., Liu, G., Gao, Y., & Zhao, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108229 · Cited by 34

IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages

Petroni, G., Galassi, C., Gouin, K. H., Chen, H., Buqué, A., Bloy, N., Yamazaki, T., Sato, A., Beltrán‐Visiedo, M., Campia, G., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01007-z · Cited by 34

Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy

Zhang, B., Zou, J., Zhang, Q., Wang, Z., Wang, N., He, S., Zhao, Y., & Naman, C. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052408 · Cited by 31

Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents

Fucikova, J. P., Palová-Jelínková, L., Klapp, V., Holíček, P., Láníčková, T., Kašíková, L., Drozenová, J., Cibula, D., Álvarez-Abril, B., García-Martínez, E., et al. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.01.010 · Cited by 32

Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents

Petroni, G., & Galluzzi, L. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1889101 · Cited by 28

Tanshinone IIA and hepatocellular carcinoma: A potential therapeutic drug

Li, H., Hu, P., Zou, Y., Yuan, L., Xu, Y., Zhang, X., Luo, X., & Zhang, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1071415 · Cited by 27

Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells

Favaretto, G., Rossi, M. N., Cuollo, L., Laffranchi, M., Cervelli, M., Soriani, A., Sozzani, S., Santoni, A., & Antonangeli, F. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03695-5 · Cited by 25

Pan-inhibition of the three H2S synthesizing enzymes restrains tumor progression and immunosuppression in breast cancer

Dawoud, A., Youness, R. A., Nafea, H., Manie, T., Bourquin, C., Szabó, C., Abdel-Kader, R. M., & Gad, M. Z. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03317-1 · Cited by 23

Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors

Klapp, V., Buqué, A., Bloy, N., Sato, A., Yamazaki, T., Zhou, X. K., Formenti, S. C., Galluzzi, L., & Petroni, G. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03964-4 · Cited by 23

The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

Schober, S. J., Schoening, C., Eck, J., Middendorf, C., Lutsch, J., Knoch, P., von Ofen, A. J., Gassmann, H., Thiede, M., Hauer, J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1961 · Cited by 24

CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors

Salewski, I., Henne, J., Engster, L., Krone, P., Schneider, B., Redwanz, C., Lemcke, H., Henze, L., Junghanß, C., & Maletzki, C. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2094583 · Cited by 23

CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules

Wu, Y., Shrestha, P., Heape, N. M., & Yarchoan, R. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03400-z · Cited by 22

Molecular Mechanism of Tanshinone against Prostate Cancer

Li, W., Huang, T., Xu, S., Che, B., Yu, Y., Zhang, W., & Tang, K. (2022) · Molecules · doi:10.3390/molecules27175594 · Cited by 21

Tumor immune checkpoints and their associated inhibitors

Gao, Z., Ling, X., Shi, C., Wang, Y., & Lin, A. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200195 · Cited by 21

Cell cycle inhibitors activate the hypoxia-induced DDX41/STING pathway to mediate antitumor immune response in liver cancer

Wong, P. Y., Chan, C. Y. K., Xue, H. D. G., Goh, C. C., Cheu, J. W., Tse, A. P., Zhang, M. S., Zhang, Y., & Wong, C. C. (2024) · JCI Insight · doi:10.1172/jci.insight.170532 · Cited by 20

Rationale for the Use of Radiation-Activated Mesenchymal Stromal/Stem Cells in Acute Respiratory Distress Syndrome

Tovar, I., Guerrero, R., López‐Peñalver, J. J., Expósito, J., & de Almodóvar, J. M. R. (2020) · Cells · doi:10.3390/cells9092015 · Cited by 17

Stable germline transgenesis using the Minos Tc1/ mariner element in the sea urchin Lytechinus pictus

Jackson, E. W., Romero, E., Kling, S., Lee, Y., Tjeerdema, E., & Hamdoun, A. M. (2024) · Development · doi:10.1242/dev.202991 · Cited by 18

C4orf19 inhibits colorectal cancer cell proliferation by competitively binding to Keap1 with TRIM25 via the USP17/Elk-1/CDK6 axis

Huang, S., Li, J., Wu, S., Zheng, Z., Wang, C., Li, H., Zhao, L., Zhang, X., Huang, H., Huang, C., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02656-z · Cited by 16

MicroRNA‑186‑3p attenuates tumorigenesis of cervical cancer by targeting MCM2

Lu, X., Song, X., Hao, X., Liu, X., Zhang, X., Yuan, N., Ma, H., & Zhang, Z. (2021) · Oncology Letters · doi:10.3892/ol.2021.12800 · Cited by 16

An Overview on the Anticancer Potential of Punarnavine: Prediction of Drug-Like Properties

Ahmad, I. I., Khan, H. Z., Amin, M. U., Khalid, S., Behl, T., & Rahman, N. U. (2021) · ONCOLOGIE · doi:10.32604/oncologie.2021.018296 · Cited by 16

ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma

Zhang, S., Xu, L., Feng, J., Tan, D., Zhu, Y., Hou, J., Li, W., Lv, K., Wang, W., Jiang, L., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.842351 · Cited by 18

Particle radiotherapy and molecular therapies: mechanisms and strategies towards clinical applications

Helm, A., Fournier, C., & Durante, M. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.2 · Cited by 15

MND1 functions as a potential prognostic biomarker associated with cell cycle and immune infiltration in kidney renal clear cell carcinoma

Fang, J., Zhen, J., Gong, Y., Ke, Y., Fu, B., Jiang, Y., Xie, J., Liu, Y., Ding, Y., Huang, D., et al. (2022) · Aging · doi:10.18632/aging.204280 · Cited by 14

Immunology of Cell Death in Cancer Immunotherapy

Galluzzi, L., & Garg, A. D. (2021) · Cells · doi:10.3390/cells10051208 · Cited by 15

CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma

Zhang, W., Shang, X., Yang, F., Han, W., Xia, H., Liu, G., Liu, Y., & Wang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.867788 · Cited by 15

Cell Cycle-Related Clinical Applications

Khan, M. G. M., & Wang, Y. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2736-5_3 · Cited by 14

Cuproptosis Combined with lncRNAs Predicts the Prognosis and Immune Microenvironment of Breast Cancer

Zhang, L., Zhang, Y., Bao, J., Gao, W., Wang, D., & Pan, H. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/5422698 · Cited by 16

Uncovering the Pharmacological Mechanism of 2-Dodecyl-6-Methoxycyclohexa-2,5 -Diene-1,4-Dione Against Lung Cancer Based on Network Pharmacology and Experimental Evaluation

Wang, L., Yang, X., Song, Q., Fu, J., Wang, W., Du, K., Chen, S., Cao, J., Huang, R., & Zou, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.617555 · Cited by 14

Identification of a novel prognostic signature for HCC and analysis of costimulatory molecule-related lncRNA AC099850.3

Wang, Q., Fang, Q., Huang, Y., Zhou, J., & Liu, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-13792-z · Cited by 14

Demethylzelasteral inhibits proliferation and EMT via repressing Wnt/β-catenin signaling in esophageal squamous cell carcinoma

Yu, J., Wang, W., Liu, B., Gu, J., Chen, S., Cui, Y., & Sun, G. (2021) · Journal of Cancer · doi:10.7150/jca.45493 · Cited by 14

Predicting drug responses of unseen cell types through transfer learning with foundation models

Wang, Y., Liu, X., Fan, Y., Xie, B., Cheng, J. S.-C., Wong, K. C., Cheung, P. P., King, I., & Li, Y. (2025) · Nature Computational Science · doi:10.1038/s43588-025-00887-6 · Cited by 14

Integrating artificial intelligence in osteosarcoma prognosis: the prognostic significance of SERPINE2 and CPT1B biomarkers

Qu, H., Jiang, J., Zhan, X., Liang, Y., Guo, Q., Liu, P., Lü, L., Yang, Y., Xu, W., Zhang, Y., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-54222-6 · Cited by 13

Hijacking monopolar spindle 1 (MPS1) for various cancer types by small molecular inhibitors: Deep insights from a decade of research and patents

Liang, C., Zhou, Y., Xin, L., Kang, K., Tian, L., Zhang, D., Li, H., Zhao, Q., Gao, H., & Shi, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116504 · Cited by 13

Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2− Breast Cancer

Ferrari, P., Schiavone, M. L., Scatena, C., & Nicolini, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073438 · Cited by 14

A novel strategy for designing the magic shotguns for distantly related target pairs

Luo, Y., Wang, P., Mou, M., Zheng, H., Hong, J., Tao, L., & Zhu, F. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac621 · Cited by 13

Innovating Cancer Treatment Through Cell Cycle, Telomerase, Angiogenesis, and Metastasis

Yousefi, T., Jobani, B. M., Taebi, R., & Qujeq, D. (2024) · DNA and Cell Biology · doi:10.1089/dna.2024.0109 · Cited by 12

Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor–positive mammary carcinogenesis

Buqué, A., Bloy, N., Petroni, G., Jiménez‐Cortegana, C., Sato, A., Iribarren, C., Yamazaki, T., Galassi, C., Hensler, M., Bhinder, B., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae329 · Cited by 12

After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor–Positive Metastatic Breast Cancer

Teysir, J., Lloyd, M. R., Alkassis, S., Callahan, R. D., Fairley, R., Wander, S. A., Bardia, A., & Jhaveri, K. L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473372 · Cited by 14

Polysaccharides from Hemerocallis citrina Baroni Inhibit the Growth of Hepatocellular Carcinoma Cells by Regulating the Wnt/β-Catenin Pathway

Sang, T., Fu, Y. J., & Song, L. J. (2023) · Nutrition and Cancer · doi:10.1080/01635581.2023.2216915 · Cited by 11

Double-Faced Immunological Effects of CDK4/6 Inhibitors on Cancer Treatment: Challenges and Perspectives

Liu, Y., Deng, Y., Yang, C., & Naranmandura, H. (2024) · Bioengineering · doi:10.3390/bioengineering11111084 · Cited by 13

Rationally designed Pyrazolo[1,5-a]pyrimidines as dual inhibitors of CA IX/XII and CDK6: A novel approach for NSCLC treatment

Elkotamy, M. S., Elkelesh, I. A., Giovannuzzi, S., Ismail, R. S. M., El-Refaie, W. M., Almehizia, A. A., Naglah, A. M., Nocentini, A., Supuran, C. T., Farès, M., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117752 · Cited by 11

Harnessing multi-omics and artificial intelligence: revolutionizing prognosis and treatment in hepatocellular carcinoma

Wang, Z., Zhou, G., Cao, R., Zhang, G., Zhang, Y., Xiao, M., Liu, L., & Zhang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1592259 · Cited by 11

AMPA Receptor Encephalitis in a Patient With Metastatic Breast Cancer Receiving Palbociclib

Matthews, E., Schmitt, B. L., Passeri, M., Mizenko, C., Orjuela, K. D., & Piquet, A. L. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200012 · Cited by 12

Network analysis reveals miRNA crosstalk between periodontitis and oral squamous cell carcinoma

Li, Z., Fu, R., Wen, X., & Zhang, L. (2023) · BMC Oral Health · doi:10.1186/s12903-022-02704-2 · Cited by 11

Comprehensive Analysis of Cell Cycle-Related Genes in Patients With Prostate Cancer

Liu, Z., Pan, R., Li, W., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.796795 · Cited by 10

Novel 3-Methyleneisoindolinones Diversified via Intramolecular Heck Cyclization Induce Oxidative Stress, Decrease Mitochondrial Membrane Potential, Disrupt Cell Cycle, and Induce Apoptosis in Head and Neck Squamous Cell Carcinoma Cells

Sharma, A., Anand, P., Padwad, Y. S., & Maurya, S. K. (2022) · ACS Omega · doi:10.1021/acsomega.2c05378 · Cited by 10

Immunodiagnostic plasma amino acid residue biomarkers detect cancer early and predict treatment response

Tang, C., Corredeira, P., Casimiro, S., Shi, Q. F., Han, Q., Sukdao, W., Cavaco, A. C. M., Melo-Alvim, C., Matos, C. O., Abreu, C. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61685-2 · Cited by 9

Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells

Tarrado‐Castellarnau, M., Foguet, C., Tarragó‐Celada, J., Palobart, M., Hernández-Carro, C., Perarnau, J., Zodda, E., Polat, I. H., Marín, S., Suárez‐Bonnet, A., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03495-w · Cited by 12

Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review

Zheng, S., Chen, Y., Zhu, Z., Li, N., He, C., Koeffler, H. P., Han, X., Wei, Q., & Xu, L. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2500021 · Cited by 9

ANKFN1 plays both protumorigenic and metastatic roles in hepatocellular carcinoma

Wang, Y., Zhang, Y., Mi, J., Jiang, C., Wang, Q., Li, X., Zhao, M., Geng, Z., Song, X., Li, J., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02380-0 · Cited by 9

Integrated Bioinformatics and Experimental Analysis Identified TRIM28 a Potential Prognostic Biomarker and Correlated with Immune Infiltrates in Liver Hepatocellular Carcinoma

Han, J., Wang, Y., Zhou, H., Ai, S., & Wan, D. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/6267851 · Cited by 9

nc‐RNA‐mediated high expression of CDK6 correlates with poor prognosis and immune infiltration in pancreatic cancer

Zhao, Y., Xu, B., Wang, F., Jiang, F., Xu, J., & Yu, D. (2022) · Cancer Medicine · doi:10.1002/cam4.5260 · Cited by 9

MPA/DMBA-driven mammary carcinomas

Buqué, A., Pérez-Lanzón, M., Petroni, G., Humeau, J., Bloy, N., Yamazaki, T., Sato, A., Kroemer, G., & Galluzzi, L. (2020) · Methods in cell biology · doi:10.1016/bs.mcb.2020.08.003 · Cited by 10

Senescence Inflames the Pancreatic Tumor Microenvironment

Petroni, G., & Galluzzi, L. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100020 · Cited by 9

Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers

Chai, A. W. Y., Yee, P. S., & Cheong, S. C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837835 · Cited by 8

Immune‐related gene signature predicts clinical outcomes and immunotherapy response in acute myeloid leukemia

Xu, Q., Cao, D., Fang, B., Yan, S., Hu, Y., & Guo, T. (2022) · Cancer Medicine · doi:10.1002/cam4.4687 · Cited by 7

Hybrid control of Turing instability and Hopf bifurcation in CDK1-APC feedback systems with diffusion

Luan, Y., Xiao, M., Wang, Z., & Zhao, J. (2023) · Journal of the Franklin Institute · doi:10.1016/j.jfranklin.2023.09.036 · Cited by 8

Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma

Chen, Y., Jin, Y., Chen, Y.-K., Cui, C., Yao, J., Zhang, Y., Li, M. H., Cao, G. F., Yang, S., Fan, Y. H., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.01.005 · Cited by 7

Assessment of transcription inhibition as a characteristic of immunogenic cell death

Cerrato, G., Humeau, J. F., Sauvat, A., Kepp, O., & Kroemer, G. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.12.026 · Cited by 6

Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2− breast cancer

Li, S., Zhang, X., & Pang, D. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113059 · Cited by 5

Assessment of type I interferon responses as a feature of immunogenic cell death

Forveille, S., Sauvat, A., Zhang, S., Zhao, L., Kroemer, G., & Kepp, O. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.12.028 · Cited by 5

Circular RNA ERBIN Promotes Proliferation of Hepatocellular Carcinoma via the miR-1263/CDK6 Axis

Yang, S., Yu, F., Ji, Y., Shen, Y., Lu, H., Gao, Y., Zhang, F., Wang, X., & Zhang, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.878513 · Cited by 5

A novel immune-related gene signature correlated with serum IL33 expression in acute myeloid leukemia prognosis.

Xie, J., Wang, W., Wang, N., Dong, Q., Han, H., Feng, Y.-P., Yuan, Y., Feng, J., & Chen, K. (2023) · PubMed Central · Cited by 5

A Novel Scoring Model of Deubiquitination Patterns Predicts Prognosis and Immunotherapeutic Response in Hepatocellular Carcinoma

Zhang, J., Wu, G., Peng, R., Cao, J., Tu, D., Zhou, J., Su, B., Jin, S., Jiang, G., Zhang, C., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101789 · Cited by 5

Revolutionizing Breast Cancer Care: Cutting-Edge Breakthroughs and Future Frontiers in Precision Medicine

Qureshi, M. A., Khan, M. Y., Imran, A., Maqsood, Q., Hussain, N., & Ali, S. W. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_254 · Cited by 5

Identification of CDK4/6 Inhibitors as Small Molecule NLRP3 Inflammasome Activators that Facilitate IL-1β Secretion and T Cell Adjuvanticity

Weiss, A. M., López, M. A., Rosenberger, M. G., Kim, J. Y., Shen, J., Chen, Q., Ung, T. W.-M., Ibeh, U., Knight, H. R., Rutledge, N. S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00516 · Cited by 4

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Pernas, S., Sanfeliu, E., Villacampa, G. J., Salvador, J., Perelló, A., González, X., Jiménez, B., Merino, M. J., Palacios, P., Pascual, T., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00710-x · Cited by 5

A N-(4-chlorophenyl)-γ-amino acid derivatives exerts in vitro anticancer activity on non-small cell lung carcinoma cells and enhances citosine arabinoside (AraC)-induced cell death via mitochondria-targeted pathway

Kavaliauskas, P., Žukauskas, Š., Anusevičius, K., Balandis, B., Vaickelionienė, R., Petraitis, V., & Mickevičius, V. (2021) · Results in Chemistry · doi:10.1016/j.rechem.2021.100193 · Cited by 5

Kinase inhibitors: Opportunities for small molecule anticancer immunotherapies

Safaroghli‐Azar, A., Emadi, F., Lenjisa, J. L., Mekonnen, L. B., & Wang, S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103525 · Cited by 5

Breast Cancer Immunity: It is TIME for the Next ChapterPreprint

Quail, D. F., Park, M., Welm, A. L., & Ekiz, H. A. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041324 · Cited by 6

CSF1R inhibitors mitigate CDK4/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+/HER2− breast cancer

Li, S., Gong, Y., Li, H., Liu, S., Yin, Y., Yu, Y., Chu, Y., Hou, J., Liu, J., Zhang, H., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03786-w · Cited by 4

MicroRNA-486: a dual-function biomarker for diagnosis and tumor immune microenvironment characterization in non-small cell lung cancer

Yu, J., Shen, Y., Xu, Y., Feng, Z., Shen, Y., Zhu, Y., Huan, J., & Peng, Q. (2025) · BMC Medical Genomics · doi:10.1186/s12920-025-02158-9 · Cited by 4

KMT 2 A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells

Brock, L., Benzien, L., Lange, S., Hühns, M., Runge, A., Roolf, C., Sekora, A., Knuebel, G., Escobar, H. M., Junghanß, C., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.13792 · Cited by 3

Contributions of marine invertebrates to our understanding of human health and disease

Hamdoun, A. M., DeTomaso, A. W., & Foltz, K. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95227-9.00015-4 · Cited by 3

Palbociclib regulates the expression of dihydrofolate reductase and the cell cycle to inhibit t (11;14) multiple myeloma

Wang, Y., Wang, H., & Wang, X. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-2830 · Cited by 3

Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors

Saavedra, C., Vallejo, A., Longo, F., Domingo, J. J. S., Fernández-Abad, M., Gión, M., López-Miranda, E., Martínez-Jáñez, N., Guerra, E. M., Chamorro, J., et al. (2023) · Cancers · doi:10.3390/cancers15072000 · Cited by 3

Immunomodulatory effects of CDK4/6 inhibitors

Zhang, S., Xu, Q., Sun, W., Zhou, J., & Zhou, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188912 · Cited by 34

To Cycle or Fight—CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity

Ameratunga, M., Kipps, E., Okines, A. F. C., & Lopez, J. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1999 · Cited by 61

Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation

Bonelli, M. A., Monica, S. L., Fumarola, C., & Alfieri, R. R. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113676 · Cited by 104

Emerging immunomodulatory effects of CDK4/6 inhibitors in breast cancer therapy: A comprehensive review

Zhang, Y., Chen, B., Lin, S., Zhang, R., Wu, J., & Chen, C. (2025) · Tumor Discovery · doi:10.36922/td025190037 · Cited by 2

Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment

Pandey, P., Khan, F., Upadhyay, T. K., & Sharangi, A. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032236 · Cited by 24